Certified by Founder
Lodge
HI-Bio
start up
United States
- South San Francisco, California
- 05/01/2024
- Series B
- $95,000,000
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
- Industry Biotechnology Research
- Website https://hibio.com/
- LinkedIn https://www.linkedin.com/company/hibio/about/
Valinor | $13,000,000 | (Dec 12, 2025)
Keeper | $4,000,000 | (Dec 12, 2025)
Cyphlens | $3,800,000 | (Dec 12, 2025)
OnCorps AI | $55,000,000 | (Dec 12, 2025)
conveyd | $3,345,837 | (Dec 12, 2025)
Ritten | $35,000,000 | (Dec 12, 2025)
Safebooks AI | $15,000,000 | (Dec 12, 2025)
Double (1) | $6,500,000 | (Dec 12, 2025)
Yonda | $15,000,000 | (Dec 12, 2025)
Medra | $52,000,000 | (Dec 12, 2025)
Cynch AI | $9,000,000 | (Dec 12, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)